Why Bristol-Myers’ lung cancer drug could still succeed despite stunning trial failure By: MarketWatch August 05, 2016 at 14:59 PM EDT Trial failure was “possibly the biggest clinical surprise of my career,” an analyst wrote. Read More >> Related Stocks: Astrazeneca Plc ADR Bristol-Myers Squibb Merck & Co Range Cancer Therapeutics Index